(Q39515202)

English

Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials

scientific article published on 11 April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

based on heuristic

inferred from title

Jose R. Arribas

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Chien-Ching Hung

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

object named as

Pablo Tebas

1

0 references

object named as

Eric Florence

5

0 references

author name string

Michael Sension

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Dan Duiculescu

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Timothy Wilkin

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Simon Vanveggel

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Marita Stevens

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Henri Deckx

10

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

ECHO and THRIVE Study Groups

11

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

language of work or name

0 references

publication date

11 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

59

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

425-434

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

HIV and HAART-Associated Dyslipidemia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Elevated triglycerides and risk of myocardial infarction in HIV-positive persons

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU234

21 January 2018

Identifiers

10.1093/CID/CIU234

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

release_jgpzm3sikbhd5p6sal7hb54vx4

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39515202&oldid=1833863124"